SERES THERAPEUTICS INC (MCRB) Stock Price, Quote, News and Overview
NASDAQ:MCRB - Nasdaq - US81750R2013 - Common Stock - Currency: USD
MCRB Quote, Performance and Key Statistics
NASDAQ:MCRB (5/12/2025, 8:00:01 PM)
7.88
+0.83 (+11.69%)
The current stock price of MCRB is 7.88 USD. In the past month the price decreased by -33.28%. In the past year, price decreased by -57.17%.
MCRB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.51 | 336.23B | ||
| AMGN | AMGEN INC | 13.24 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 13.41 | 129.26B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.95B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.99 | 62.15B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.15B | ||
| ARGX | ARGENX SE - ADR | 95.55 | 34.25B | ||
| ONC | BEIGENE LTD-ADR | 5.82 | 25.14B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.38B | ||
| NTRA | NATERA INC | N/A | 21.38B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.76B | ||
| BIIB | BIOGEN INC | 7.86 | 18.23B |
Related stock screener links
About MCRB
Company Profile
Seres Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2015-06-26. Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The company is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Company Info
SERES THERAPEUTICS INC
101 Cambridge Park Drive
Cambridge MASSACHUSETTS 02139 US
CEO: Eric D. Shaff
Employees: 103
Phone: 16179459626
SERES THERAPEUTICS INC / MCRB FAQ
What is the stock price of SERES THERAPEUTICS INC today?
The current stock price of MCRB is 7.88 USD. The price increased by 11.69% in the last trading session.
What is the ticker symbol for SERES THERAPEUTICS INC stock?
The exchange symbol of SERES THERAPEUTICS INC is MCRB and it is listed on the Nasdaq exchange.
On which exchange is MCRB stock listed?
MCRB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SERES THERAPEUTICS INC stock?
12 analysts have analysed MCRB and the average price target is 93.69 USD. This implies a price increase of 1088.92% is expected in the next year compared to the current price of 7.88. Check the SERES THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SERES THERAPEUTICS INC worth?
SERES THERAPEUTICS INC (MCRB) has a market capitalization of 68.71M USD. This makes MCRB a Micro Cap stock.
How many employees does SERES THERAPEUTICS INC have?
SERES THERAPEUTICS INC (MCRB) currently has 103 employees.
What are the support and resistance levels for SERES THERAPEUTICS INC (MCRB) stock?
SERES THERAPEUTICS INC (MCRB) has a resistance level at 10.36. Check the full technical report for a detailed analysis of MCRB support and resistance levels.
Should I buy SERES THERAPEUTICS INC (MCRB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MCRB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MCRB, evaluating the profitability, health, valuation and growth aspects
- SERES THERAPEUTICS INC (MCRB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SERES THERAPEUTICS INC (MCRB) Sales and EPS estimates to see what analysts future expectations are.
- SERES THERAPEUTICS INC (MCRB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SERES THERAPEUTICS INC (MCRB) Insider and Institutional Ownership to learn about the owners and their transactions.
- SERES THERAPEUTICS INC (MCRB) Stock Chart to make your own analysis
- SERES THERAPEUTICS INC (MCRB) Latest news and press-releases to stay up to date.
Does SERES THERAPEUTICS INC (MCRB) stock pay dividends?
MCRB does not pay a dividend.
When does SERES THERAPEUTICS INC (MCRB) report earnings?
SERES THERAPEUTICS INC (MCRB) will report earnings on 2025-08-11, before the market open.
What is the Price/Earnings (PE) ratio of SERES THERAPEUTICS INC (MCRB)?
SERES THERAPEUTICS INC (MCRB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-16.96).
MCRB Technical Analysis
MCRB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MCRB. The financial health of MCRB is average, but there are quite some concerns on its profitability.
MCRB Financial Highlights
Over the last trailing twelve months MCRB reported a non-GAAP Earnings per Share(EPS) of -16.96. The EPS decreased by -41.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 0.1% | ||
| ROE | 0.99% | ||
| Debt/Equity | 0 |
MCRB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to MCRB. The Buy consensus is the average rating of analysts ratings from 12 analysts.